Research letterTofacitinib therapy for children with severe alopecia areata
References (5)
- et al.
Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients
J Am Acad Dermatol
(2017) - et al.
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
J Am Acad Dermatol
(2017)
There are more references available in the full text version of this article.
Cited by (41)
Treatment of pediatric alopecia areata: A systematic review
2022, Journal of the American Academy of DermatologyCitation Excerpt :Clinical trials are currently evaluating the efficacy of tofacitinib to treat AA in adults.99 Six case series and reports evaluated systemic tofacitinib for the treatment of AA in 28 pediatric patients.95-100 Of these patients, 82% showed complete or partial response and all nonresponders were patients with AU.
Pediatric Game Changers∗: Oral tofacitinib for the treatment of alopecia areata in children
2021, Journal of the American Academy of DermatologyTreatment Options for Alopecia Areata in Children and Adolescents
2024, Pediatric DrugsTofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review
2024, Skin Research and TechnologyGuidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment
2023, Annals of DermatologyAlopecia Areata: An Updated Review for 2023
2023, Journal of Cutaneous Medicine and Surgery
Funding sources: Supported by the Ministry of Science and Technology, R.O.C. (grant MOST 105-2628-B-010-016-MY3) and Taipei Veterans General Hospital (grants VN107-10 and V107C-124).
Conflicts of interest: None disclosed.
Reprints not available from the authors.
© 2019 by the American Academy of Dermatology, Inc.